Test For Named Disease, Body Condition Or Organ Function Patents (Class 436/811)
-
Patent number: 6665652Abstract: A method for diagnosing whether a patient has a disease comprising interpreting the results of an immunoassay, wherein the immunoassay is viewed as a series of separate tests performed in parallel. The immunoassay can be a Western blot and the disease can be Lyme Disease.Type: GrantFiled: July 27, 2000Date of Patent: December 16, 2003Inventor: Richard B. Porwancher
-
Patent number: 6653066Abstract: Disclosed is a device and method of use for detecting polyvalent analytes such as antibody to the AIDS virus, utilizing an inverse sandwich method. The test device comprises a first substance having an epitope, bound to a label and capable of moving within the test device. The test device further comprises a second substance immobilized to the test device and spatially separated from the first substance. The second substance has an epitope substantially similar to the epitope of the first substance. Upon application to the test device, the polyvalent analyte binds to the first substance and moves within the test device to the location of the second substance with both polyvalent analyte and first substance are immobilized at location of the second substance. Polyvalent analyte is detected by the presence of the label at the location of the second substance. Also disclosed is a control substance for use with the device that can be used to determine completion of the test and viability of the device.Type: GrantFiled: June 17, 1994Date of Patent: November 25, 2003Assignee: Trinity BiotechInventor: Siegfried R. Krutzik
-
Patent number: 6649344Abstract: The present invention relates to an assay for at least one predictive marker in a sample from a mammal wherein a specific reaction for at least one predictive marker indicates when non-fertilizable ova capable of in vitro maturation (IVM) and subsequent in vitro fertilization (IVF) are present in the mammal. This is particularly useful in the determination of when non-fertilizable ova, if aspirated, after in vitro maturation to MF-II will be capable of fertilization and pregnancy after implantation into the female mammal. The assay is based on a sample selected from the group consisting of body secrete, sputum, blood, urine, uterus secretes and cells.Type: GrantFiled: March 13, 2001Date of Patent: November 18, 2003Assignee: Medi-Cult A/SInventors: Svend Lindenberg, Anne Lis Mikkelsen
-
Patent number: 6645734Abstract: A monoclonal antibody binding selectively to neurosin obtained from hybridomas, in particular, strain 2B2-6 and strain S2E5 showing stable proliferation ability. These hydridomas are obtained by fusing mouse spleen cells having a high antibody titer against neurosin with mouse-derived myeloma cells, screening fused cells being highly reactive with neurosin, and thus producing an antibody binding specifically to neurosin. By using this antibody, various diseases in which neurosin participates can be diagnosed.Type: GrantFiled: December 21, 2000Date of Patent: November 11, 2003Assignee: Fuso Pharmaceutical Industries, Ltd.Inventors: Katsuya Kominami, Akira Okui, Shinichi Mitsui, Nozomi Yamaguchi
-
Patent number: 6638723Abstract: A method of diagnosing an autoimmune disease is disclosed which involves determining whether autoantibodies from a body fluid react with a microtubule organizing center (MTOC). This diagnostic procedure provides a simple, highly specific, and highly reliable diagnosis of autoimmune disease, including rheumatoid arthritis.Type: GrantFiled: February 9, 1998Date of Patent: October 28, 2003Inventor: Think You Kim
-
Patent number: 6627396Abstract: A sensor for the detection of tetrameric multivalent neuraminidase within a sample is disclosed, where a positive detection indicates the presence of a target virus within the sample. Also disclosed is a trifunctional composition of matter including a trifunctional linker moiety with groups bonded thereto including (a) an alkyl chain adapted for attachment to a substrate, (b) a fluorescent moiety capable of generating a fluorescent signal, and (c) a recognition moiety having a spacer group of a defined length thereon, the recognition moiety capable of binding with tetrameric multivalent neuraminidase.Type: GrantFiled: October 27, 2000Date of Patent: September 30, 2003Assignee: The Regents of the University of CaliforniaInventors: Basil I. Swanson, Xuedong Song, Clifford Unkefer, Louis A. Silks, III, Jurgen G. Schmidt
-
Patent number: 6623981Abstract: This invention relates to the detection of patients at risk for developing integrin antagonist/agonist mediated disease states. This invention relates to assays useful for the detection in a patient bodily fluid sample of drug-dependent antibodies which bind to integrins, or intergrin-associated proteins or complexes thereof in the presence of an integrin antagonist/agonist. This invention also relates to assays useful for the detection in a patient bodily fluid sample of drug-dependent antibodies (DDABS) that bind to integrins, including the platelet glycoprotein IIb/IIIa (GPIIb/IIIa), in the presence of a integrin agonist and/or antagonist. This invention also relates to procedures for identifying integrin antagonists/agonists that are less prone to elicit integrin antagonist/agonist mediated disease states. This invention also relates to procedures which increase the recovery of integrin-directed antibodies in body fluids, resulting in an increased sensitivity and specificity of DDAB detection assays.Type: GrantFiled: January 26, 1999Date of Patent: September 23, 2003Assignee: Bristol-Myers Squibb CompanyInventors: Jeffrey T. Billheimer, Dietmar A. Seiffert, Leah A. Breth, Timothy C. Burn, Ira B. Dicker, Henry J. George, Gregory F. Hollis, Jeannine M. Hollis, Jennifer E. Kochie, Karyn T. O'Neil
-
Patent number: 6613535Abstract: This invention relates to a method for establishing and using a decision marker by which positive samples can be discriminated from negative samples. The method employs the analysis of multiple samples from confirmed positive and negative samples. A fluorescence channel is selected so that the desired sensitivity and specificity are achieved. A microparticle having this fluorescence channel then is made and is used in conjunction with a fluorescence marker which is specific for the population of interest.Type: GrantFiled: October 29, 1992Date of Patent: September 2, 2003Assignee: Becton, Dickinson andCompanyInventors: Joachim Albrecht, Frank Hulstaert, Rosette Becker
-
Patent number: 6613530Abstract: The invention concerns a method for the immunological determination of a specific antibody in a sample liquid in which the sample liquid is incubated in the presence of a solid phase with two antigens directed against the antibody to be determined of which the first antigen carries at least one marker group and the second antigen is (a) bound to the solid phase or (b) is present in a form capable of binding to the solid phase and the antibody to be determined is detected by determining the marker group in the solid phase or/and in the liquid phase characterized in that at least one of the two antigens contains several epitope regions which react with the antibody to be determined.Type: GrantFiled: January 24, 1997Date of Patent: September 2, 2003Assignee: Roche Diagnostics GmbHInventors: Ursula-Henrike Wienhues, Cornelia Kruse-Müller, Eva Höss, Elke Faatz, Beatus Ofenloch-Hähnle, Christoph Seidel, Michael Wiedmann
-
Patent number: 6613537Abstract: The present invention is drawn to pyrrolopyridinium derivatives having a new structural skeleton, preferably containing an intramolecular hemiacetal, which is clearly different from any known Advanced Glycation Endproduct (AGE) and which, when present in an organism, has a bioactivity unlike the conventional AGE. The present invention provides pyrrolopyridinium derivatives and pharmaceutically acceptable salts thereof, an antibody prepared from said derivatives as a hapten, a method for the diagnosis of diabetes, diabetic complications, renal failure, dialysis-related complications, amyloidosis, aging, diseases accompanied by aging, etc. using said derivatives or an antibody prepared therefrom and a method for evaluating effectiveness of pharmaceuticals used to treat diabetes, diabetes-related diseases, dialysis-related complications, aging, diseases accompanied by aging, etc.Type: GrantFiled: February 28, 2001Date of Patent: September 2, 2003Assignee: Nippon Zoki Pharmaceutical Co., Ltd.Inventors: Ko Nakamura, Seikoh Horiuchi, Norie Araki
-
Patent number: 6610496Abstract: A method for predicting animal growth performance, which includes administering a suitable amount of growth hormone releasing hormone (GHRH) to an animal, observing levels of growth hormone (GH) subsequent to GHRH administration and; predicting growth and fat development in an the animal from observed levels of GH.Type: GrantFiled: July 8, 1999Date of Patent: August 26, 2003Assignee: University of Maryland, College ParkInventors: Geoffrey E. Dahl, Scott M. Barao, Erin E. Connor
-
Publication number: 20030148530Abstract: Devices for cost-effectively performing in-vitro diagnostic chemical analyses at multiple distributed locations within a medical institution are disclosed. One object of this invention is to provide a network of distributed sensory devices that acquire sensor signals from blood specimens and deliver those signals through a connection to a central location for analysis by a general-purpose computer and generation of an analysis result. The analysis result is then sent to numerous locations on a network for display, including also possibly back to the location of signal acquisition. Cost-effective mobile sensing devices are also disclosed. The present system includes blood-sensor signal acquisition devices distributed throughout the hospital. The sensory signal-acquisition devices are card readers that acquire raw sensory signals from diagnostic cards inserted therein.Type: ApplicationFiled: June 8, 2001Publication date: August 7, 2003Inventor: Imants R. Lauks
-
Patent number: 6599756Abstract: Methods of detecting antibodies to one or more glycosphingolipid(s) of interest in a sample are disclosed which comprise using a solid-phase reactant having carbonyl groups attached thereon, and the glycosphingolipid(s) of interest linked to the solid-phase reactant by an amide bond between an amino group of the glycosphingolipid of interest and a carbonyl group attached to the solid-phase reactant. The methods of detecting antibodies to glycosphingolipid(s) of interest can be used in methods of diagnosing autoimmune diseases in an individual.Type: GrantFiled: July 27, 2000Date of Patent: July 29, 2003Assignee: Athena Diagnostics, Inc.Inventors: Normand J. Robichaud, Louis P. Kertiles
-
Patent number: 6589748Abstract: A method is disclosed for diagnosing early stage of a disease in which an intact protein found in urine is an indicator of the disease. The method includes assaying urine sample to detect the presence of modified protein using either immunological or non-immunological technique. Methods for preventing and treating the disease are also disclosed.Type: GrantFiled: June 28, 2001Date of Patent: July 8, 2003Assignee: Monash UniversityInventor: Wayne D. Comper
-
Patent number: 6582928Abstract: The invention provides heterobifunctional cross-linking reagents and methods of using the cross-linking reagents. The cross-linking reagents of the invention combine a nucleophilic hydrazide residue with an electrophilic maleimide residue allowing coupling of aldehydes to free thiols. In the methods of the invention, human immunodeficiency virus (HIV) infected cells can be detected using conjugates that include CD4 molecules conjugated to detectable markers via the disclosed cross-linking reagents.Type: GrantFiled: March 2, 2000Date of Patent: June 24, 2003Assignee: Genentech, Inc.Inventors: Avi J. Ashkenazi, Steven M. Chamow, Timothy P. Kogan
-
Patent number: 6579968Abstract: Compositions and methods are provided for treatment of sexual dysfunction in mammals, including male sexual dysfunction, such as erectile dysfunction, and female sexual dysfunction. In one embodiment, a peptide-based composition including the peptide sequence Ac-Nle-cyclo(-Asp-His-D-Phe-Arg-Trp-Lys)-OH is administered. Methods of administration include injection, oral, nasal and mucosal administration.Type: GrantFiled: June 28, 2000Date of Patent: June 17, 2003Assignee: Palatin Technologies, Inc.Inventors: Christine H. Blood, Annette M. Shadiack, Joanna K. Bernstein, Guy H. Herbert
-
Patent number: 6579684Abstract: This invention is a method of identifying the presence of, and monitoring, a disease state in a mammal which is associated with degradation of connective tissue in the mammal. The method detects and determines whether diagnostically or prognostically significant levels of YKL-40 protein and/or YKL-40 peptide are present in a biological sample. The method can be used, for example, to identify the presence of inflammatory or degenerative joint disease or degeneration of connective tissue in organs. Serum YKL-40 levels as detected and quantified by the inventive method are also suggestive of the prognosis for the length of survival in breast cancer patients following recurrence and/or metastasis of their cancers. The figure shows the elution position of substantially pure serum YKL-40 on a gel filtration column.Type: GrantFiled: March 4, 1999Date of Patent: June 17, 2003Assignee: The Regents of the University of CaliforniaInventors: Paul A. Price, Julia S. Johansen
-
Patent number: 6576429Abstract: An apparatus for taking an intestinal sample of a human or animal patient comprises a holder part (1) and an expandable part (2) supported by the holder part and having one or more sampling areas (8) on the surface thereof. The expandable part (2) is in a non-expanded state rectally insertable into and retractable from the patient's intestine, and in an expanded state, inserted into the patient's intestine, the expandable part is capable of contacting the intestinal wall with at least one sampling area (8; 14). The apparatus further comprises protective livers (7a, 7b) for preventing said sampling area or areas (8) from contact with the intestinal wall and intestinal fluid at least when the expandable part (2) in the non-expanded state is being rectally inserted into the patient's intestine.Type: GrantFiled: October 26, 2000Date of Patent: June 10, 2003Assignee: Alimenta Diagnostics ABInventor: Roger Hällgren
-
Patent number: 6566082Abstract: The OX-40 antigen is characterized and claimed together with variants and derivatives thereof. Also described are binding agents for the antigen and the use of these in diagnosis and therapy. Examples of such use include a method for the selective depletion of activated CD4+ T-cells in vivo by using immunotoxins comprising an OX-40 antibody conjugated to a toxic molecule (such as Ricin-A chain). The administration of these specific immunotoxins is used therapeutically to deplete autoimmune reactive CD4+ T-cells which have been implicated in diseases including Multiple Sclerosis, Rheumatoid Arthritis, Sarcoidosis, and Autoimmune Uveitis as well as inflammatory bowel disease and graft-versus-host disease. This type of therapy is also beneficial for eradicating CD4+ T-cell lymphomas and alloreactive CD4+ T-cells involved with a transplantation reaction. The use of the human form of the OX-40 antibody will also help in the early diagnosis of all the diseases mentioned above.Type: GrantFiled: June 6, 1995Date of Patent: May 20, 2003Inventors: Andrew D. Weinberg, Arthur A. Vandenbark
-
Patent number: 6558961Abstract: Methods for assessing immunocompetence, cellular or humoral immunity, antigen exposure, or allergic conditions in an individual by accelerating diagnostic particles into a target skin site in the individual are provided.Type: GrantFiled: September 3, 1999Date of Patent: May 6, 2003Assignee: PowderJect Research LimitedInventors: David F. Sarphie, Lee K. Roberts, Deborah L. Fuller
-
Patent number: 6551791Abstract: A method and device for rapidly, non-invasively and inexpensively differentiating between allergic rhinitis, upper respiratory tract viral infection and bacterial sinusitis, comprising a support strip upon which is fixed discrete indicators of pH, protein content, nitrite content, leukocyte esterase activity, and eosinophil content or other measure of a substance found in allergic secretions, such as TAME esterase, of a sample with which said reagent test strip is contacted. Contact of a nasal secretion with the device of this invention permits differentiation between allergic, bacterial and viral conditions, based on pH, protein content, leukocyte esterase activity, nitrite content, eosinophil content and TAME esterase activity. The invention further provides a novel means for collecting nasal secretions to facilitate differential diagnosis of sinusitis, upper respiratory tract viral infection and allergic rhinitis.Type: GrantFiled: June 19, 2000Date of Patent: April 22, 2003Assignee: University of FloridaInventors: Parker Small, Shih-Wen Huang, Ronald Kudla
-
Patent number: 6544800Abstract: Novel sensor devices composed of a crystalline colloidal array (CCA) polymerized in a hydrogel are disclosed. The hydrogels are characterized as being capable of shrinking and swelling in response to specific stimuli applied thereto. As the hydrogels shrink or swell, the lattice structure of the CCA embedded therein changes, thereby changing the wavelength of light diffracted by the CCA. Thus by monitoring the change in diffracted wavelength, the concentration of a stimulus is determined. The gels can be modified to sense numerous different stimuli. The sensor devices are specific in that they are modified to react with only one species or family of species. These sensors have various applications in areas including, for example, environmental and chemical systems, chemomechanical systems, sensor devices and medical diagnostic tools. Various methods for making and using these devices are also disclosed.Type: GrantFiled: January 3, 2001Date of Patent: April 8, 2003Assignee: University of PittsburghInventor: Sanford A. Asher
-
Patent number: 6537760Abstract: In a competitive receptor binding assay for detecting TSH-receptor auto-antibodies in a biological sample, the sample is reacted in a reaction mixture which contains (i) a TSH-receptor or TSH-receptor preparation; (ii) a primary competitor, for example labelled TSH; and (iii) an agent for separating a complex composed of the TSH-receptor and the elements bound thereto of the reaction mixture from the liquid phase. According to the invention, the reaction is carried out in the presence of at least one monoclonal or polyclonal antibody specific against a partial peptide sequence of the TSH eceptor. This specific antibody is used to immobilize a complex of TSH-receptor and primary competitor and/or as secondary competitor for another part of the TSH-receptor auto-antibodies expected in a sample. The primary or secondary competitors are or can be selectively labelled.Type: GrantFiled: August 4, 1999Date of Patent: March 25, 2003Assignee: B.R.A.H.M.S. AktiengesellschaftInventors: Andreas Bergmann, Joachim Struck
-
Patent number: 6534282Abstract: A method to assess hypertension by measuring the amount of free and conjugated hydroxyeicosatrienoic acids (DHETs) and metabolites of DHETs, which are metabolites of arachidonic acid (AA) epoxygenases and epoxide hydrolases, in a biological sample which contains the DHETs (using any methods including GC/MS or ELISA) is disclosed. The method further included determining the amount of molecules containing a DHET-specific epitope immunoreactive with antibodies produced against DHETs present in the sample. This amount is compared with a control sample(s). Hypertension is determined through the comparison wherein the amount of increase of free and conjugated DHETs and metabolites of DHETs in the sample isolated from an organism. The present invention also provides a method to assess catalytic activity of AA epoxygenases using immunoassays by subtracting the amounts of NADPH-independent epoxyeicosatriencic acids (EETs) from total (NADPH-dependent+independent) EETs.Type: GrantFiled: September 4, 2001Date of Patent: March 18, 2003Inventors: Hyesook Kim, Jorge H. Capdevila, Raymond R. Novak, Deanna Kroetz
-
Patent number: 6534281Abstract: An immunoassay for selectively measuring human C-peptide as well as a kit therefor is disclosed. In the method, human C-peptide contained in a sample, a first anti-human C-peptide antibody, and a second anti-human C-peptide antibody which is immobilized on a solid support are reacted to form an immune complex among these three components. The formed immune complex is separated from the non-reacted antibodies and sample; and then the separated immune complex is quantified. The first antibody recognizes an epitope existing in the region from 1st to 16th amino acid residue from the N-terminal of the human C-peptide, and the second antibody recognizes an epitope existing in the region from 1st to 16th amino acid residue from the N-terminal of human C-peptide; with the proviso that the first and second antibodies do not recognize the same epitope so that they can simultaneously bind to said human C-peptide.Type: GrantFiled: June 12, 2001Date of Patent: March 18, 2003Assignee: Fujirebio Inc.Inventors: Sachiko Kitajima, Yoshihiro Kurano, Kaoru Nakatsubo, Isao Nishizono
-
Patent number: 6528323Abstract: A test strip adapted to receive a sample and detect an analyte therein is provided. The test strip comprises a sample addition zone to which a sample may be added; an absorbent zone proximal to the sample addition zone; one or more test zones distal to the sample addition zone, at least one of the test zones including a first analyte binding agent immobilized therein which is capable of binding to the analyte to be detected; and a terminal sample flow zone distal to the one or more test zones, the absorbent zone being positioned relative to the sample addition zone and having an absorption capacity relative to the other zones of the test strip such that a distal diffusion front of a sample added to the sample addition zone diffuses from the sample addition zone to a distal diffusion point within the terminal sample flow zone and then reverses direction and diffuses proximal relative to the one or more test zones.Type: GrantFiled: June 14, 1999Date of Patent: March 4, 2003Assignee: Praxsys Biosystems, Inc.Inventors: Richard M. Thayer, Alan J. Polito, Robert K. Dinello, George H. Sierra, Henry J. Wieck
-
Patent number: 6514716Abstract: The subject matter of this invention is a method of determining terminal sialic acid residues in human transferrin according to a sandwich principle, which is characterized in that the sample fluid containing the human transferrin is incubated with a first receptor which binds specifically to human transferrin, the thus-formed complex is separated from the sample fluid and incubated with a second receptor which binds specifically to terminal sialic acid residues in human transferrin, the second receptor being bound or able to bind to a marker, and the complex made up of the first receptor, human transferrin and the second receptor is determined with the marker. According to one embodiment, the method of the invention allows the determination of sialic-acid-deficient human transferrin in body fluids.Type: GrantFiled: May 20, 2000Date of Patent: February 4, 2003Inventor: Atou Lô
-
Patent number: 6514714Abstract: The present invention provides an improved method for detection of panel reactive antibodies in serum of a subject against HLA class I antigens, which comprises the steps of adding serum from a subject to an array of microbeads, each microbead presenting HLA antigens from a cell population presenting the same HLA antigens; incubating the serum and microbeads for sufficient time for anti-HLA antibodies in the serum to bind to the HLA antigens presented on the microbeads; removing the serum components which do not specifically bind with the HLA antigens presented on the microbeads; incubating the microbeads with a labeled ligand capable of specifically binding with anti-HLA antibodies bound to said HLA antigens; removing the labeled ligand which is not bound to said HLA antigens; and detecting the presence of labeled ligand bound to said HLA antigens by flow cytometry.Type: GrantFiled: April 17, 2000Date of Patent: February 4, 2003Assignee: One LambdaInventors: Jar-How Lee, Rui Pei
-
Patent number: 6509462Abstract: The present invention provides a highly sensitive immunoassay system for estrogens, which utilizes as a labeled compound a biotinylated estradiol derivative of the formula (1) wherein one of R1 and R2 is hydrogen and the other is a group represented by wherein R3s are the same or different and represent an arginine residue or a lysine residue, x is 0 or 1, y is an integer from 1 to 5, and z is an integer from 1 to 3.Type: GrantFiled: July 17, 2001Date of Patent: January 21, 2003Assignees: Otsuka Pharmaceutical Co., Ltd., Yanaihara Institute, Inc.Inventors: Noboru Yanaihara, Ikuo Kato, Kazuyuki Kitamura, Tsukasa Kodaira
-
Patent number: 6503722Abstract: This invention provides methods, compositions, and kits for detecting the presence of toxigenic strains of C. difficile in a biological sample. One embodiment provides methods for C. difficile detection that involve assaying for both C. difficile glutamate dehydrogenase and C. difficile toxin A or toxin B. In another embodiment, the invention provides a highly sensitive assay for C. difficile toxin A that is useful for determining whether a C. difficile strain is toxigenic. This embodiment involves binding of toxin A to a moiety that reversibly binds to a capture moiety present on a magnetic bead. A magnetic field is applied to the sample to concentrate the toxin A, after which the magnetic beads are dissociated and removed from the solution to obtain a highly concentrated preparation of toxin A, thus making possible a very sensitive assay.Type: GrantFiled: July 29, 1999Date of Patent: January 7, 2003Assignee: Biosite DiagnosticsInventor: Gunars E. Valkirs
-
Patent number: 6498038Abstract: Disclosed is a method for determining alcohol intake or alcohol induced liver damage in a subject by quantifying the content of sialic acid in apolipoprotein J (Apo J). In particular the present invention involves the steps of (a) providing a sample containing Apo J from a subject; (b) purifying the Apo J from the sample; (c) determining sialylation index, i.e., moles of sialic acid peer mole of Apo J in the sample; and (d) evaluating whether the sialylation index is an indication of alcohol intake or alcohol related liver damage recovery from alcohol addiction or alcohol relapse in the subject.Type: GrantFiled: January 13, 2000Date of Patent: December 24, 2002Assignee: Bioprobes, Inc.Inventors: Pradeep Ghosh, Raj Lakshman, Eric Anthony Hale
-
Publication number: 20020187520Abstract: The invention relates to the use of a secretor variant cell-line expressing the alpha moiety of human IgE binding protein to determine the allergic status of a given individual. Moreover, the cell-line is also used to provide an assay system for determining the allergenicity of substances and for subsequently providing therapeutic compostions which render said substances ineffective. In addition, the invention also relates to the use of said cell-line to determine the IgE independent irritancy of substances and compositions effective for attenuating the effects of said substances.Type: ApplicationFiled: August 12, 1998Publication date: December 12, 2002Inventors: BIRGIT ANNA HELM, ANNE WILSON, DENISE MOREIRA-MACHADO
-
Patent number: 6491643Abstract: A breath test analyzer, which analyzes exhaled breaths of a patient for isotope labeled products generated in the patient's body after ingestion by the patient of an isotope labeled substance, where the presence of these isotope labeled products provide an indication of a medical condition in the patient. The analyzer uses a very sensitive infra-red spectrophotometer, which enables it to continuously collect and analyze multiple samples of the patient's breath, and process the outputs in real time, while the patient is still connected to the analyzer, such that a definitive result is obtained within a short time, such as the order of a few minutes. The breath test analyzer is sufficiently small that it can be easily accomodated in the office of a physician. The breath test analyzer can be utilized for a number of diagnostic breath tests, according to the isotope labeled substance ingested by the patient and the gases detected in the patient's breath.Type: GrantFiled: January 22, 2001Date of Patent: December 10, 2002Assignee: Oridion Medical Ltd.Inventors: Daniel E. Katzman, Ephraim Carlebach
-
Patent number: 6485987Abstract: The present invention relates to methods and compositions for the direct detection of analytes using color changes that occur in immobilized biopolymeric material in response to selective binding of analytes to their surface. In particular, the present invention provides methods and compositions related to the encapsulation of biopolymeric material into metal oxide glass using the sol-gel method.Type: GrantFiled: February 8, 2000Date of Patent: November 26, 2002Assignees: Regents of the University of California, Sandia CorporationInventors: Deborah H. Charych, Darryl Sasaki, Stacey Yamanaka
-
Patent number: 6482648Abstract: The present invention relates to methods for the production of a stable troponin preparation and its use as a calibrator and/or control in immunoassays. The formulation is prepared from mammalian, preferably bovine, heart tissue which provides a calibrator/control composition which remains stable over a long period of time.Type: GrantFiled: October 14, 1997Date of Patent: November 19, 2002Assignee: Bayer CorporationInventors: Margit Doth, Christoph Petry
-
Patent number: 6479015Abstract: An apparatus for monitoring a level of a chemical species in a body fluid includes a fluid collection layer adapted for receiving the body fluid. The fluid collection layer is dry prior to being brought into contact with the body fluid. A catalyst is provided in, on, or near the fluid collection layer so as to be in contact with the body fluid in the fluid collection layer. The catalyst facilitates a reaction of the chemical species in the body fluid. An indicator, responsive to the reaction of the chemical species, is also provided in, on, or near the fluid collection layer. A characteristic of the indicator changes in response to the reaction of the chemical species, thereby indicating the level of the chemical species in the body fluid. This apparatus can be used, for example, to monitor the level of lactate in perspiration during activities, such as exercise or other athletic exertions.Type: GrantFiled: March 3, 1998Date of Patent: November 12, 2002Assignee: Pepex Biomedical, LLCInventors: Nathan R. Long, Eric A. Peper, James L. Say, Mark S. Vreeke
-
Patent number: 6475748Abstract: Disclosed is a method for differentiating human peripheral blood granulocytes which comprises cultivating the granulocytes in the presence of an interferon and acting an immune complex on said granulocytes in the presence of a chemiluminescent substance, and measuring the chemiluminescent amounts induced. It contributes to the screening of patients suffering from serious infectious diseases or a range of inflammations, and is advantageous for monitoring the curative effects for those patients.Type: GrantFiled: May 16, 1994Date of Patent: November 5, 2002Assignee: Pola Chemical Industries, Inc.Inventors: Toshiro Majima, Ryoichi Nagatomi, Tasuke Konno, Toshikazu Awataguchi, Yoshimi Yano
-
Patent number: 6475442Abstract: This invention provides a kit for use in a method for detecting gastric damage. The kit comprises: (a) a sealed container of sterilized buffered aqueous sucrose solution; and (b) a urine collection device suitable for collection and storage of human urine.Type: GrantFiled: March 9, 1998Date of Patent: November 5, 2002Assignee: G. D. Searle & Co.Inventors: Glenn L. Thompson, Dan Giampuzzi
-
Patent number: 6461827Abstract: The present invention provides a method for detecting or predicting ischemic disorders in a subject by using as an indication the concentration of human lipocalin-type prostaglandin D synthase (hPGDS) in body fluid samples from the subject. More specifically, the method comprises comparing the hPGDS concentrations in the body fluid samples from a subject with the reference values established for a normal subject, thereby detecting or predicting the ischemic disorders.Type: GrantFiled: October 29, 1999Date of Patent: October 8, 2002Assignees: Mauha Corporation, Osaka Bioscience InstituteInventors: Hiroshi Oda, Nobuyuki Sato, Masazumi Nishikawa, Kosuke Seiki, Yoshihiro Urade, Yutaka Eguchi, Naomi Eguchi
-
Patent number: 6458549Abstract: A method is described to diagnose (1) renal salt wasting syndrome and (2) Alzheimer's disease among dementia patients by measuring a patient's level of prostaglandin D2 synthase. Methods are also described to (1) treat renal salt wasting syndrome, (2) inhibit the rate of apoptosis or (3) prevent the onset of, or slow the rate of, progression of Alzheimer's disease. These methods involve inhibiting the rate of -&Dgr;12prostaglandin J2 synthesis or by inhibiting the activity of -&Dgr;12prostaglandin J2.Type: GrantFiled: June 11, 1998Date of Patent: October 1, 2002Assignee: Winthrop-University HospitalInventor: John K. Maesaka
-
Publication number: 20020131893Abstract: The invention concerns a home kit and a method for detection of food allergies by determining the presence of antibodies against specific antigens in a stool sample.Type: ApplicationFiled: March 15, 2001Publication date: September 19, 2002Inventor: Martin Jerome Lee
-
Patent number: 6451611Abstract: The invention is for a method of quantitatively analysing the hexose monophosphate (HMP) composition of a biological sample, preferably a dried blood sample, using tandem mass spectrometry and for a method for quantitatively analysing the abundance of amino acids acylcarnitines and HMP from the same biological sample (such as a dried blood spot sample). The method is useful in screening infants for galactosemia and can be integrated with a method of screening for disorders in the metabolism of amino acids, organic acids and fatty acids.Type: GrantFiled: July 28, 2000Date of Patent: September 17, 2002Assignee: Statens Serum InstituteInventors: Henrik Simonsen, Ulrich Glümer Jensen, Niels Jacob Brandt, Ernst Christensen
-
Patent number: 6447989Abstract: A method is disclosed for diagnosing early stage of a disease in which an intact protein found in urine is an indicator of the disease. The method includes assaying urine sample to detect the presence of modified protein using either immunological or non-immunological technique. Methods for preventing and treating the disease are also disclosed.Type: GrantFiled: October 12, 1999Date of Patent: September 10, 2002Assignee: Monash UniversityInventor: Wayne D. Comper
-
Patent number: 6440682Abstract: A method to assess hypertension by measuring the amount of free and conjugated hydroxyeicosatrienoic acids (DHETS) and metabolites of DHETs, which are metabolites of arachidonic acid (AA) epoxygenases and epoxide hydrolases, in a biological sample which contains the DHETs (using any methods including GC/MS or ELISA) is disclosed. The method further included determining the amount of molecules containing a DHET-specific epitope immunoreactive with antibodies produced against DHETs present in the sample. This amount is compared with a control sample(s). Hypertension is determined through the comparison wherein the amount of increase of free and conjugated DHETs and metabolites of DHETs in the sample isolated from an organism. The present invention also provides a method to assess catalytic activity of AA epoxygenases using immunoassays by measuring the amounts of NADPH-independent epoxyeicosatrienoic acids (EETs) and total (NADPH-dependent+independent) EETs.Type: GrantFiled: May 24, 2000Date of Patent: August 27, 2002Assignee: Detroit R&D Inc.Inventors: Hyesook Kim, Jorge H. Capdevila, Raymond R. Novak, Deanna Kroetz
-
Patent number: 6432656Abstract: The present invention features calcilytic compounds. “calcilytic compounds” refer to compounds able to inhibit calcium receptor activity. Also described are the use of calcilytic compounds to inhibit calcium receptor activity and/or achieve a beneficial effect in a patient; and techniques which can be used to obtain additional calcilytic compounds.Type: GrantFiled: August 6, 1999Date of Patent: August 13, 2002Assignee: NPS Pharmaceuticals, Inc.Inventors: Eric G. Del Mar, Robert M. Barmore, Derek Sheehan, Bradford C. Van Wagenen, James F. Callahan, Richard M. Keenan, Nikesh R. Kotecha, Maria Amparo Lago, Linda Sue Southall, Mervyn Thompson
-
Patent number: 6429024Abstract: A test method for IgA nephropathy involves determining antibody, which recognizes the core peptide of the hinge region in IgA1, in specimens. The method is a rapid and sample test method for IgA nephropathy having less emotional distress for the patients, low risk for peripheral hemorrhage of the kidney and reduced financial burden for the patients.Type: GrantFiled: November 13, 2000Date of Patent: August 6, 2002Assignee: Asahi Kasei Kabushiki KaishaInventors: Tohru Kokubo, Kenji Arai, Kazunori Toma
-
Patent number: 6423503Abstract: A method of distinguishing prostate cancer from benign prostatic hyperplasia (BPH) is provided. The mathematical combination or ratio of proPSA and BPSA serum or tissue markers may be used for distinguishing benign prostatic hyperplasia (BPH) from prostate cancer. It is the discovery of the present invention that BPSA is preferentially elevated in transition zone prostate tissue whereas pPSA is elevated in the peripheral zone of prostate tissue. A kit for aiding in distinguishing BPH from prostate cancer is also provided.Type: GrantFiled: April 30, 1999Date of Patent: July 23, 2002Assignees: Hybritech Incorporated, Baylor College of MedicineInventors: Stephen D. Mikolajczyk, Tang Jang Wang, Harry G. Rittenhouse, Robert L. Wolfert, Kevin Slawin
-
Patent number: 6410341Abstract: An analytical test device is described for the immunochromatographic determination of the presence of one or more analytes in fluid samples. The device is configured such that the sample is allowed to enter the detection zone simultaneously from many different directions, eliminating stagnation of the flow of the sample. By selection of the porous substrate, the device also allows for the separation of red blood cells from plasma, providing a rapid test for one or more analytes in a sample of whole blood. The device of the present invention may measure more than one analyte simultaneously from a single sample, either by having multiple immunochromatographic pathways fed by a single sample, or multiple analytes detected in the same pathway by way of multiple capture antibodies.Type: GrantFiled: July 14, 1999Date of Patent: June 25, 2002Assignee: Spectral Diagnostics, Inc.Inventors: Helmut E. Freitag, Qinwei Shi, Charles A. Harrington
-
Patent number: 6406860Abstract: This invention provides an improved assays for the detection of transmissable spongiform encephalopathies (TSEs) in humans and non-human mammals. The methods involve detecting the presence or absence of 14-3-3 proteins in cerebrospinal fluid from the tested organism. Elevated levels of 14-3-3 are indicative of transmissable spongiform encephalopathies, in particular Cretzfeldt-Jacob disease in humans or mad cow disease in bovines).Type: GrantFiled: June 7, 1999Date of Patent: June 18, 2002Assignees: The United States of America as represented by the Department of Health and Human Services, California Institute of TechnologyInventors: Gary Hsich, Kimbra Kenney, Clarence J. Gibbs, Jr., Michael G. Harrington
-
Patent number: 6391644Abstract: Apparatus for indicating the propensity of a subject to formation of urinary stones comprising apparatus for optically observing a urine sample from a subject under magnification and an image analyzer operative to determine the existence of crystalline bodies in the urine sample and to provide an output indication thereof.Type: GrantFiled: January 18, 1999Date of Patent: May 21, 2002Inventor: Dan Gottlieb